CIRM Funded Clinical Trials

Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial.

Disease Area:

Melanoma

Investigator:

Robert Dillman

Institution:

Caladrius Biosciences

CIRM Grant:

CLIN2-08239 (Closed)

Award Value:

$3,000,000.00

Trial Sponsor:

Caladrius Biosciences

Trial Stage:

Phase 3

Trial Status:

Closed

Targeted Enrollment:

4

ClinicalTrials.gov ID:

NCT01875653

Details:

NeoStem, which later changed its name to Caladrius BioScience, ran a Phase 3 trial targeting cancer stem cells. These cells are believed to be able to survive chemotherapy and other cancer-targeting treatments, and can cause a relapse by enabling tumors to grow and spread. This approach used the patient’s own tumor cells to create a personalized therapy, one designed to engage the patient’s own immune system and destroy the cancer. The trial was halted by Caladrius in January 2016 for business reasons.